Ritter Pharmaceuticals (NASDAQ: RTTR) is a specialty pharmaceutical company developing therapeutics that modulate the gut microbiome to treat gastrointestinal diseases. The company’s first novel microbiome modulator, RP-G28, is currently in a phase 2b/3 study in humans for the treatment of lactose intolerance. More than one billion people suffer from lactose intolerance globally, and the company believes RP-G28 has the potential to become the first FDA-approved drug for the treatment of the disease. In previous human studies, RP-G28 has demonstrated significant beneficial changes to the gut microbiome that have been associated with supporting metabolic health. Recently, the company announced a collaborative effort with the Food for Health Center at the University of Nebraska to study the role of the microbiome and Ritter’s RP-G28 in metabolic syndrome. The pre-clinical research is intended to build upon previously published studies suggesting that prebiotics may support improvements in clinical measurements associated with metabolic syndrome.
To learn more, visit www.RitterPharma.com
About Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
